Prophase Labs (PRPH) Status Update summary

Strategic merger and LOI details

• Entered a non-binding LOI for a reverse merger with Advanced Biological Laboratories S.A. (ABL), with ABL to own approximately 76% of the combined entity and a preliminary valuation of up to $30 million.

• The merger aims to leverage synergies in diagnostics and distribution across the US and Europe, focusing on genomics, diagnostics, and consumer health.

• Transaction is subject to due diligence, definitive agreements, regulatory approvals, and Nasdaq requirements, with no breakup fees or penalties if abandoned.

• Parties anticipate executing definitive documentation within 60 to 90 days, with the CEO to present details in a virtual conference call.

• Post-merger, the board will include the current CEO, with further composition to be determined, and the current management team expected to lead the U.S. subsidiary.

Value distribution and carve-outs

• Current shareholders will receive a special cash dividend of up to $10 million funded from new capital raised in the merger.

• Crown Medical Collections receivables, estimated at $50 million net, will be carved out for current shareholders, with litigation against insurers progressing and settlements anticipated soon.

• Combined company to assume only about $5 million of existing indebtedness; other legacy liabilities remain with ProPhase.

• No breakup fees or penalties if the transaction is abandoned; each party bears its own costs.

Business verticals and asset updates

• The BE-Smart esophageal cancer test targets a $7–14 billion market, has full USPTO patent approval, >95% technical success rate, and is being commercialized with collaborations and a Clinical Science Advisory Board.

• Nebula Genomics, now profitable on a pro forma basis, possesses a 16-petabyte DNA dataset and offers whole genome sequencing, with DNA Complete and DNA Expand products launched.

• The supplements business may be developed further depending on available capital.

• Completed major restructuring: sold Pharmaloz Manufacturing, shut down Nebula Genomics lab, and reduced headcount and IT overhead.